Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00158977 · ClinicalTrials.gov registry record · Phase 3

Contak Renewal 3 AVT

A Phase 3 study, sponsored by Boston Scientific Corporation.

Completed
Registry status
Phase 3
Development phase
73
Enrollment target

NCT00158977 is a Phase 3 study that has completed, run by Boston Scientific Corporation. The registered enrollment target is 73 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00158977, a Phase 3 study, has completed, sponsored by Boston Scientific Corporation.

COMPLETED
Registry status
Phase 3
Development phase
73 participants
Enrollment target

Study Summary

The RENEWAL 3 AVT device is designed to treat patients suffering from HF, with a history of or at risk of developing atrial and ventricular arrhythmias

Interventions

  • DEVICE CONTAK RENEWAL 3 AVT

Trial Details

FieldValue
Enrollment Target 73 participants
Start Date 2003-11
Est. Completion 2008-02
Phase Phase 3

Sponsor

Boston Scientific Corporation

280 total trials

What the Registry Record Tells You About NCT00158977

The ClinicalTrials.gov registry entry for NCT00158977 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 73 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Scientific Corporation, which has 280 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which CONTAK RENEWAL 3 AVT is the first listed.

NCT00158977 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00158977 about?

NCT00158977 is a clinical study titled "Contak Renewal 3 AVT". The RENEWAL 3 AVT device is designed to treat patients suffering from HF, with a history of or at risk of developing atrial and ventricular arrhythmias

What is the current status of trial NCT00158977?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 73 participants. The study started on 2003-11. Estimated completion is 2008-02.

What interventions are being tested in trial NCT00158977?

The interventions under investigation include: CONTAK RENEWAL 3 AVT (DEVICE).

Who is sponsoring clinical trial NCT00158977?

This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.